Efrat Kochba
Technik-/Wissenschafts-/F&E-Leiter bei NanoPass Technologies Ltd.
Profil
Efrat Kochba is currently working as the Medical Director at NanoPass Technologies Ltd.
She previously worked as a Manager-Medical & Clinical Trials at Roche Pharmaceuticals, Inc. and as a Principal at TransPharma Medical Ltd.
Dr. Kochba holds a doctorate degree from The Hebrew University of Jerusalem.
Aktive Positionen von Efrat Kochba
Unternehmen | Position | Beginn |
---|---|---|
NanoPass Technologies Ltd.
NanoPass Technologies Ltd. Pharmaceuticals: MajorHealth Technology NanoPass Technologies Ltd. develops and manufactures pharmaceuticals. It offers MicronJet needle which is a painless Intradermal Injection. The company was founded by Shuki Yeshurun in 2000 and is headquartered in Ness Ziona, Israel. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 |
Ehemalige bekannte Positionen von Efrat Kochba
Unternehmen | Position | Ende |
---|---|---|
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Corporate Officer/Principal | - |
Ausbildung von Efrat Kochba
The Hebrew University of Jerusalem | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
NanoPass Technologies Ltd.
NanoPass Technologies Ltd. Pharmaceuticals: MajorHealth Technology NanoPass Technologies Ltd. develops and manufactures pharmaceuticals. It offers MicronJet needle which is a painless Intradermal Injection. The company was founded by Shuki Yeshurun in 2000 and is headquartered in Ness Ziona, Israel. | Health Technology |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |